Additionally, the company recorded robust growth across both its B2B and B2C channels, supported by a balanced combination of increased volumes and product mix improvements.
B2C revenue grew by around 19% and B2B revenue by approximately 30% on YoY basis, driven by strong specialty growth and a higher B2B contribution in core diagnostics; additionally, TruHealth Wellness and specialty segments recorded growth of around 25% and approsimately 29%, respectively on Y-o-Y basis in Q4 FY26.
Excluding the recent acquisitions of Core Diagnostics, DAPIC, Scientific and Ambika, revenue grew by around 14.5% YoY, largely on account of increased patient and test volume, and product mix. EBITDA margins for the quarter improved on a Y-o-Y basis, driven by operating leverage and efficiency gains.
Metropolis Healthcare is India’s second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics.
On a consolidated basis, profit after tax (PAT) rose 33.7% YoY to Rs 42 crore in Q3FY26, compared with Rs 31 crore in Q3FY25. Revenue from operations increased 25.8% YoY to Rs 406 crore in Q3FY26, compared with Rs 323 crore in Q3FY25.
The scrip shed 0.20% to end at Rs 422.95 on the BSE. The stock market will remain closed today, 4 April 2026, on account of Good Friday.